 |
Indication & Dosage |
| |
| |
| Intravenous |
| MANAGEMENT OF UNSTABLE ANGINA |
| Adult:
Initial loading dose of 0.4 mcg/kg/min for 30 min, as soon as possible after diagnosis, followed by 0.1 mcg/kg/min for at least 24-48 hr. Patients undergoing percutaneous coronary intervention (PCI): loading dose of 0.4 mcg/kg/min for 30 minutes followed by 0.1 mcg/kg/min given during angiography and for 12–24 hr after angioplasty or atherectomy. Patients who require CABG: discontinue tirofiban at least 4–6 hr before CABG. All patients should receive aspirin before start of tirofiban therapy and unfractionated heparin simultaneously with the start of tirofiban therapy, unless contra-indicated.The entire duration of tirofiban treatment should not exceed 108 hrs. |
| |
| Intravenous |
| NON-ST-SEGMENT ELEVATION MI |
| Adult:
Loading dose: 0.4 mcg/kg/minute for 30 minutes followed by 0.1 mcg/kg/minute for at least 24-48 hr. Patients undergoing percutaneous coronary intervention (PCI): Loading dose: 0.4 mcg/kg/minute for 30 minutes followed by 0.1 mcg/kg/minute given during angiography and for 12–24 hr after angioplasty or atherectomy. Patients who require CABG: Discontinue tirofiban at least 4–6 hr before CABG. All patients should receive aspirin before start of tirofiban therapy and unfractionated heparin simultaneously with the start of tirofiban therapy, unless contra-indicated. Max duration of treatment: 108 hr. |
|
| |
|
| Precautions |
Anaemia, thrombocytopenia or known history of platelet function disturbance. Puncture of a non-compressible vessel within 24 hr, recent epidural procedure, severe CHF, cardiogenic shock. Discontinue in case of uncontrolled bleeding or require emergency surgery or thrombolytic therapy. Severe renal impairment. Monitor platelet counts, haematocrit and haemoglobin before and periodically (e.g. within the first 6 hr of the loading infusion and daily thereafter). Monitor activated clotting time (ACT) or aPTT if on concurrent heparin therapy. Defer PCI for at least 4 hr after initiation of therapy. Elderly, females, patients with low body weight. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Bleeding, thrombocytopenia, bradycardia, dissection of the coronary artery, dizziness, oedema, pelvic pain, sweating, nausea, fever, headache, rashes. |
| |
|
| Adverse Drug Reactions |
Anaphylaxis. |
| |
|
|
|
